A comprehensive review of the role of lncRNAs in gastric cancer (GC) pathogenesis, immune regulation, and their clinical applications

Siri, Goli; Yazdani, Omid; Esbati, Romina; Akhavanfar, Roozbeh; Asadi, Fatemeh; Adili, Ali; Ebrahimzadeh, Farnoosh; Hosseini, Seyed Mahmoud Eshagh

doi:10.1016/j.prp.2022.154221

Cited by 3 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the selected genes analysed in this paper, it is worth paying attention to the participation of long non-coding RNAs (lncRNAs), which can regulate target genes at the level of transcription, post-transcription and translation by modifying mRNA, miRNA and proteins. Therefore, attention should be paid to the need to use the widest possible research that can shed light on the development of gastritis and gastric cancer after H.pylori infection, to fully define the microenvironment associated with this process, and to identify new biomarkers and therapeutic targets [ 68 ].…”

Section: Discussionmentioning

confidence: 99%

Mutations in Helicobacter pylori infected patients with chronic gastritis, intestinal type of gastric cancer and familial gastric cancer

Hnatyszyn,

Szalata,

Zielińska

et al. 2024

Hered Cancer Clin Pract

View full text Add to dashboard Cite

Background Development of sequential changes of mucous leading to gastric cancer and familial cases of gastric cancer of intestinal type is widely connected with Helicobacter pylori infections. In this study we analysed variants of genes involved in cancerogenesis and inflammatory processes of intestines in patients infected with H.pylori. Our goal was to test whether mutations in these genes predestinate to development of gastric cancer, and whether there is a genetic factor that makes it more likely for infections with H.pylori to cause gastric cancer. As infections with H. pylori are relatively common, discovering such genetic predispositions could be used for establishing risk-groups and for planning treatments. Methods Our studies cover analysis of variants in genes involved in cancerogenesis: TP53 (rs11540652, rs587782329, COSM10771), MSH2 (rs193922376), MLH1 (rs63750217), and inflammatory processes of intestine: NOD2 (rs2066847, rs2066842), IL1A (rs1800587) and IL1B (rs1143634) from H.pylori-infected patients. Results Mutations were more common in the group of patients with gastric cancer of intestinal type and familial cases of gastric cancer in comparison with patients with chronic gastritis, chronic atrophic gastritis, intestinal metaplasia, dysplasia or gastric cancer (p-value = 0.00824), with the prevalence of p53 mutations in patients with familial gastric cancer vs. patients with other changes of mucosa (p-value = 0.000049). Additionally, gastric cancer patients have mainly genotype TT or CT of the rs2066842 variant of the NOD2 gene. Conclusions The lack of statistically significant changes of other interleukin genes involved in inflammatory processes may suggest the presence of H.pylori infection as a potential trigger for the development of the inflammatory process of the mucosa, leading through microbiota dysbiosis to the development of enteric gastric cancer. Mutations in analysed genes correlated with more severe mucosal changes, with a much more frequent presence of TP53 gene mutations, with a limited presence of other mutations in the familial history of gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Mutations in Helicobacter pylori infected patients with chronic gastritis, intestinal type of gastric cancer and familial gastric cancer

Hnatyszyn,

Szalata,

Zielińska

et al. 2024

Hered Cancer Clin Pract

View full text Add to dashboard Cite

show abstract

“…In recent years, the treatment of GC has considerably improved with the continuous progress of surgical techniques and the diversification of therapeutic means. However, poor surgical effects and serious chemotherapy resistance are still unavoidable problems for many advanced GC patients [19][20][21]. Therefore, identifying new targets for diagnosis and treatment while constructing new diagnosis and treatment prediction models are effective strategies for treating GC.…”

Section: Discussionmentioning

confidence: 99%

Aberrant expression of AKR1B1 indicates poor prognosis and promotes gastric cancer progression by regulating the AKT-mTOR pathway

Liu,

Zhu,

Cheng

et al. 2023

Aging

View full text Add to dashboard Cite

Gastric cancer (GC) is a common malignant tumor in the digestive tract and a major cause of global cancer death. Due to the limited access to early screening, many patients are diagnosed with advanced GC. Therefore, postoperative radiotherapy and chemotherapy possess limited efficacy in treating GC. AKR1B1 has been associated with tumorigenesis and metastasis across various tumors, becoming a potential therapeutic target for GC. However, its role and mechanism in GC remain unclear. In this study, AKR1B1 was elevated in GC tissue, depicting a poor prognosis. AKR1B1 is closely related to age, vascular and neural invasion, lymph node metastasis, and the TNM stage of GC. The developed survival prediction model suggested that AKR1B1 expression level is crucial in the prognosis of GC patients. Moreover, the expression level of AKR1B1 in GC tissues is closely associated with the AKT-mTOR pathway. In vitro and in vivo assays functional assays helped determine the oncogenic role of AKR1B1. Additionally, the knockdown of AKR1B1 expression level in GC cell lines could effectively suppress the AKT-mTOR pathway and inhibit the proliferation and migration of tumor cells. In conclusion, this study provides a theoretical basis to establish the potential association and regulatory mechanism of AKR1B1 while offering a new strategy for GC-targeted therapy.

show abstract

Unrevealing the vital role of ncRNAs in Gastric Cancer chemoresistance

Kazemi,

Goodarzi,

Daneshipour

et al. 2023

Pathology - Research and Practice

View full text Add to dashboard Cite

A comprehensive review of the role of lncRNAs in gastric cancer (GC) pathogenesis, immune regulation, and their clinical applications

Cited by 3 publications

References 95 publications

Mutations in Helicobacter pylori infected patients with chronic gastritis, intestinal type of gastric cancer and familial gastric cancer

Mutations in Helicobacter pylori infected patients with chronic gastritis, intestinal type of gastric cancer and familial gastric cancer

Aberrant expression of AKR1B1 indicates poor prognosis and promotes gastric cancer progression by regulating the AKT-mTOR pathway

Unrevealing the vital role of ncRNAs in Gastric Cancer chemoresistance

Contact Info

Product

Resources

About